Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors. On Feb. 2, 2026, Harold Bernstein, President, R&D & CMO of Maze Therapeutics (MAZE 2.19%), exercised 15,000 options and immediately sold the resulting shares in an open-market transaction, fully divesting his direct ownership, according to a SEC Form 4 filing. Transaction summaryMetricValueShares sold (direct)15,000Transaction value~$690,300Post-transaction shares (direct)0Transaction value based on SEC Form 4 weighted average purchase price ($46.02). Key questionsWhat was the nature and structure of this transaction?This was a derivative transaction involving the exercise of 15,000 stock options, immediately followed by the open-market sale of the resulting shares. How does the transaction relate to Bernstein’s available share capacity and recent activity?This sale exhausted Bernstein’s remaining direct share capacity, following a series of administrative transactions that reduced his holdings from 90,000 shares to 0 over the past year. Company overviewMetricValuePrice (as of 2/14/26)$46.01Market capitalization$2.21 billionNet loss (TTM)$101.46 million1-year price change284.06%* 1-year price change calculated using Feb. 14, 2026 as the reference date. Company snapshotMaze Therapeutics is a clinical-stage biotechnology company that develops small-molecule precision medicines targeting renal (kidney), cardiovascular, and metabolic diseases, as well as obesity. Its lead candidate medicines include ones that help with kidney disease. What this transaction means for investorsBernstein’s sale shouldn’t concern investors, as it was part of a 10b5-1 trading plan that allows insiders to prearrange the purchase or sale of shares. And even though he doesn’t hold any direct shares, he still holds nearly 300,000 stock options after the Feb. 2 sale was conducted. There have been many instances in which, once a company has its IPO and share prices shoot up following the market debut, they fall back, and the price settles and becomes less volatile for a few months, if not years. But for Maze, after its first four months on the market, the stock posted nine straight months of gains, soaring 158% for the entire year of 2025, just after its IPO on Jan. 31, 2025. While the stock may eventually experience a brief drawdown amid so much significant bullish momentum, it’s widely considered a strong buy among Wall St analysts and continues to advance in clinical trials for multiple medicines. Read NextFeb 1, 2026 •By Adé HennisMaze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's StockStocks MentionedMaze TherapeuticsNASDAQ: MAZE$46.01 (2.19%) $1.03*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.